Q-Linea
Q-linea AB is a Swedish medical technology company developing rapid infection diagnostics and antimicrobial susceptibility testing systems. The company develops and commercializes ASTar, an automated instrument and consumable disc platform enabling rapid phenotypic AST directly from positive blood cultures. Main revenue drivers consist of sales of ASTar instruments and single-use reagent consumables alongside distribution agreement milestones. Q-linea serves hospital microbiology laboratories, clinical diagnostic centers, and infectious disease specialists across Europe and North America. The company holds an innovative niche position in rapid blood infection diagnostics and antibiotic resistance testing. Headquartered in Uppsala, Sweden, Q-linea AB is listed on Nasdaq Stockholm.
2 of the funds FundTelligence covers report a position in Q-Linea.
- Legal name
- Q-Linea AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Q-Linea
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)